ABSTRACT Lactobacillus reuteri CECT8605 has shown potential probiotic properties in both in vitro and in vivo assays. Besides its beneficial characteristics, general aspects concerning genetic stability and safety for human consumption have been studied. Its genome sequence has been a useful tool to support preliminary conclusions based on empirical observations. L actobacillus reuteri CECT8605 has exhibited several biological activities with promising applications in the field of human health (1, 2). However, such beneficial characteristics are not the only important factors in selecting a microorganism as a possible probiotic. The genetic stability of microorganisms, determined in many cases by the presence of active prophages or extrachromosomal genetic elements, as well as their resistance to antimicrobial agents, are important aspects that determine their technological feasibility and its safety. The genome of L. reuteri CECT8605 was sequenced in order to characterize this microorganism in these directions in more detail.
genome contains other genes involved in peptidoglycan synthesis and cell division, but does not contain genetic mobile elements. These preliminary results seem to indicate that a transfer event of ampicillin resistance to other microorganisms is unlikely to occur.
Accession number(s).
The complete genome sequence of L. reuteri CECT8605 has been deposited in GenBank under accession number MWVS00000000 (BioProject no. PRJNA377846).
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